HPV Vaccine, Imiquimod, and Metformin Combination Trial

The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate skin-to-skin contact. The trial will also monitor the safety of these treatments. The main questions it aims to answer are: Does the combination of treatments help the participant's body fight the cancer more effectively when used alongside standard therapy? What side effects or medical issues arise when using these experimental treatments? Researchers will use three experimenta

Trial Details

NCT ID
NCT06686043
Phase
PHASE2
Sponsor
Baylor College of Medicine
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • HPV vaccine, Imiquimod, and metformin combination therapy
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Participants must have histologically confirmed locally advanced or metastatic cervical carcinoma (Stage IB2-IVB), vaginal, or vulvar carcinoma (St…
  • Participants must have measurable disease, per Recist criteria. See Section 12 (Measurement of Effect) for the evaluation of measurable disease. Ra…
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • Participants must be ≥ 18 years of age

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →